Profile of blonanserin for the treatment of schizophrenia

Neuropsychiatric Disease and Treatment
Tomomi TenjinNoboru Yamaguchi

Abstract

Blonanserin was developed as an antipsychotic drug in Japan and approved for the treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and acts as an antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors, but displays relatively high affinity for 5-HT6 receptors. In several short-term double-blind clinical trials, blonanserin had equal efficacy as haloperidol and risperidone for positive symptoms in patients with chronic schizophrenia and was also superior to haloperidol for improving negative symptoms. Blonanserin is generally well tolerated and has a low propensity to cause metabolic side effects and prolactin elevation. We recently reported that blonanserin can improve some types of cognitive function associated with prefrontal cortical function in patients with first-episode and chronic schizophrenia. Taken together, these results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia. Further comparative studies are warranted to clarify the benefit/risk profile of blonanserin and its role in the treatm...Continue Reading

References

May 25, 2016·The Psychiatric Clinics of North America·Ganesh GopalakrishnaJohn Lauriello
Sep 13, 2015·Pharmacology, Biochemistry, and Behavior·Ayaka TataraYukihiro Ohno
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi
Aug 1, 2014·Behavioural Brain Research·Davide Amato
Aug 15, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hirotake HidaYukihiro Noda
Jun 28, 2016·Pharmacology & Therapeutics·Gian Marco LeggioFilippo Drago
Jun 11, 2016·Psychiatry and Clinical Neurosciences·Takahiko Nagamine
Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic
Sep 20, 2017·Journal of Psychopharmacology·Yusuke NakataMasaomi Iyo
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Jul 24, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Jung Suk LeeChan-Hyung Kim
Jan 29, 2016·Clinical Neuropharmacology·Yasuhide NagoshiKenji Fukui
Jun 22, 2018·Annals of General Psychiatry·Eun Hyun SeoHyung-Jun Yoon
Sep 19, 2020·Patient Preference and Adherence·Brennan Carrithers, Rif S El-Mallakh

Citations

Mar 30, 2000·The American Journal of Psychiatry·R M BilderJeffrey Lieberman
Dec 7, 2002·Psychiatry Research·Yasuhiro KanedaTetsuro Ohmori
Sep 21, 2005·The New England Journal of Medicine·Jeffrey LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 22, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mié MatsuiMasayoshi Kurachi
Dec 18, 2007·Psychiatry and Clinical Neurosciences·Yasuhiro KanedaTetsuro Ohmori
Dec 5, 2008·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang WölwerGerman Study Group on First Episode Schizophrenia
May 6, 2009·Neuropsychology·Raquelle I Mesholam-GatelyLarry J Seidman
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananSchizophrenia Patient Outcomes Research Team (PORT)
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
May 22, 2010·European Journal of Clinical Pharmacology·Junji SaruwatariSunao Kaneko
Nov 12, 2010·Nature·Thomas R Insel
Feb 16, 2011·The Australian and New Zealand Journal of Psychiatry·Vasilis P Bozikas, Christina Andreou
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomoko InoueNoboru Yamaguchi
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Sep 26, 2012·Clinical Schizophrenia & Related Psychoses·Nobumi MiyakeL Fredrik Jarskog

Related Concepts

Histamine Measurement
Metabolic Process, Cellular
PRL
Pyridines
Assay OF Haloperidol
Phenyl
Schizophrenia
Serotonin Measurement
HTR2A wt Allele
Serotonin

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here